Physician profile
Gary M Deshazo
NPI 1568512101
$2,816.30
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $525 · 2021: $720 · 2022: $1,034 · 2023: $33.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $33.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $33.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $625.91 | 2020-2023 | Vraylar |
| Novo Nordisk INC | $228.69 | 2019-2022 | |
| Astellas Pharma US INC | $198.95 | 2020-2022 | |
| Amgen INC. | $184.92 | 2019-2021 | |
| Amarin Pharma, INC. | $164.60 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.04 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $123.81 | 2020-2022 | |
| Antares Pharma, INC. | $120.82 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $120.48 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $102.42 | 2021-2022 | |
| Glaxosmithkline, LLC. | $84.65 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $83.75 | 2022 | |
| Eisai INC. | $69.72 | 2020-2021 | |
| Allergan, INC. | $55.32 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $53.23 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $44.19 | 2019 | |
| Endo Pharmaceuticals INC. | $40.00 | 2019-2020 | |
| Pfizer INC. | $39.92 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $37.67 | 2021 | |
| Harmony Biosciences LLC | $32.62 | 2021 | |
| Ibsa Pharma INC. | $29.24 | 2020-2022 | |
| Forte Bio-Pharma LLC | $24.95 | 2019 | |
| Esperion Therapeutics, INC. | $22.63 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.96 | 2022 | |
| Almatica Pharma LLC | $19.34 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $19.08 | 2021 | |
| Arbor Pharmaceuticals, INC. | $18.17 | 2020 | |
| Smith+Nephew, INC. | $16.63 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.21 | 2019 | |
| Exact Sciences Corporation | $15.86 | 2023 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $14.63 | 2022 | |
| Horizon Therapeutics Plc | $14.29 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.89 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $12.83 | 2019 | |
| Genentech USA, INC. | $12.44 | 2021 | |
| Inogen, INC. | $4.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Deshazo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.